William Hartsell, M.D. Medical Director

Slides:



Advertisements
Similar presentations
بسم الله الرحمن الرحيم ﴿و قل رب زدنى علماً﴾ صدق الله العظيم.
Advertisements

Background/Purpose ATRT is a rare and aggressive CNS tumor usually presenting in very young children (age less than 5 years). Aggressive treatments have.
A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.
Energy deposition and neutron background studies for a low energy proton therapy facility Roxana Rata*, Roger Barlow* * International Institute for Accelerator.
BROOKLYN 2 RADIOTHERAPY Patries HERST Sat 31 st Aug 2013 Session 1 / Talk 1 09:20 – 09:46 ABSTRACT Purpose. Acute radiation-induced cystitis is a common.
Radiotherapy in prostate cancer Dr.Mina Tajvidi Radiation oncologist.
Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.
Radiation and Prostate Cancer Past, Present and Future Dr
BIOLOGICAL EFFICIENCY OF A THERAPEUTIC PROTON BEAM: A STUDY OF HUMAN MELANOMA CELL LINE I. Petrović 1, A. Ristić-Fira 1, D. Todorović 1, L. Korićanac 1,
Simulating Potential Layouts for a Proton Therapy Treatment Center Stuart Price-University of Maryland Bruce Golden- University of Maryland Edward Wasil-
IMRT for the Treatment of Anal Cancer Kristen O’Donnell, MS3 December 12, 2007.
Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):
Научно-практический центр протонной лучевой терапии и радиохирургии (Москва-Дубна) A SYSTEM FOR MEASUREMENT OF A THERAPEUTIC PROTON BEAM DOSE DISTRIBUTION.
Mark L. Merlin, M.D. Radiotherapy Clinics of Georgia 7/14/2010 The Role of Radiation Therapy in the Management of Prostate Cancer.
Bragg Peak By: Megan Whitley. Bragg Peak  Bragg Peak is the characteristic exhibited by protons that makes them SO appealing for cancer treatment. 
Clinico-Dosimetric Correlation for Acute and Chronic Gastrointestinal Toxicity in Patients of Locally Advanced Carcinoma Cervix Treated With Conventional.
Prostate Support Group Dr Duncan McLaren Consultant Oncologist.
Learn More At: CyberKnife Radiosurgery in the Treatment of Early and Advanced (Oligo-Metastases) Breast Cancer Sandra Vermeulen,
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
Corresponding author Name; 2015 North Jefferson St; Three-Year Analysis of Urinary Toxicity in Two Prospective Trials.
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.
Alemtuzumab BLA committee CD52 Expression Leukocytes B- lymphocytes T- lymphocytes Monocytes Macrophages Thymocytes Granulocytes (
A Proton Therapy Overview Richard Eckart And David Turberville Richard Eckart And David Turberville.
SARC018: A SARC PILOT MULTICENTER STUDY OF PREOPERATIVE RADIATION AND SURGERY IN PATIENTS WITH HIGH- RISK DESMOID TUMORS Robert S. Benjamin, M.D.
 Multidisciplinary Effort › Surgery › Radiation › Systemic Rx (chemo, “drugs”)
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Stereotactic Body Radiation Therapy for Early Stage Prostate Cancer: Outcomes from a Single Institution Study Stereotactic Body Radiation Therapy for Early.
Debra Freeman, MD – Naples Christopher King, MD, PhD - Stanford.
Vice President and Chief Medical Physicist
Dose Calculations for Cyberknife Stereotactic Body Radiation Therapy For CK, one can fractionate the therapy yet remain convenient and non-invasive for.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS.
Lung SBRT Implementation at the Regional Cancer Centre
J Cho, G Ibbott, M Kerr, R Amos, and O Mawlawi
J Cho, G Ibbott, M Gillin, C Gonzalez-Lepera, U Titt and O Mawlawi
TMIST A Breast Cancer Screening Trial
Modern Radiation Oncology
By: Matthew Kosch Advantages and Recent Implementation of Fiducials in Image-Guided Radiation Therapy.
Radiation therapy for Early Stage Prostate Cancer
1 Stone RM et al. Proc ASH 2015;Abstract 6.
Kasey Etreni BSc., MRT(T), RTT, CTIC
Hypofractionated radiotherapy for breast cancer
CCO Independent Conference Coverage
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Evaluation Of RTOG Guidelines For Monte Carlo Based Lung SBRT Planning
IMRT delivery of preoperative, high dose radiotherapy to a large volume, with Simultaneous Integrated Boost (SIB) in retroperitoneal sarcomas: The Ottawa.
RTOG 0126 A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer Bijoy.
Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.
أجهزة العلاج الإشعاعي Clinical Radiation Generator
Information for participating Sites
Insert tables Insert figure
Median Volume (cc) of GTV Receiving Dose
Volumetric Modulated Arc Therapy (VMAT) versus Intensity Modulated Radiation Therapy (IMRT) for Anal Carcinoma Heather Ortega, BSRT(T), CMD, Kerry Hibbitts,
Insert tables Insert graphs Insert figure
European Urology Oncology
A Multi-Institutional Dosimetric Evaluation of Proton Versus Photon Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma F. Khan, B. Nguyen,
Adjuvant Radiation is Required for Gastric Cancer
External Beam Radiotherapy as Curative Treatment of Prostate Cancer
Coiffier B et al. Proc ASH 2011;Abstract 265.
An Evaluation of Prostate Volume and Proton Therapy-Related Toxicities
Jesse Conterato, BA&Sc. RSNA 2016
Particle Therapy Cooperative Group North America Annual Conference
Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &
Rectal toxicity for patients treated with proton beam radiation diagnosed with prostate cancer using free rectal water, water filled rectal balloon or.
Proton Beam Therapy for Liver Cancer is Well Tolerated: Outcomes from the Proton Collaborative Group REG Trial Michael Chuong, M.D.1,2, Smith Apisarnthanarx,
Planning techniques of proton boost
Results: Purpose/Objectives: Methods: Conclusions:
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Average Dose-Volume Ratio
Clinical Outcomes after Proton Partial Breast Radiotherapy for Early Stage- Hormone Receptor Positive Breast Cancer: 3-Year Outcomes of a Phase II Trial.
Presentation transcript:

Hypofractionated Vs. Standard Fractionation Proton Therapy For Prostate Cancer: PCG GU002-10 William Hartsell, M.D. Medical Director CDH Proton Center – A ProCure Center Warrenville, Illinois USA

Hypofractionated Vs. Standard Fractionation Proton Therapy For Prostate Cancer: PCG GU002-10 Carlos Vargas1,  William Hartsell2,  Kimberly Hahn3,  Doug Smidebush3,  John Han-Chih Chang2,  Lori Abruscato2,  Angela Piper3,  Sameer Keole4 1Florida Radiation Oncology Group, Jacksonville, FL, USA 2CDH Proton Center - A ProCure Center, Warrenville, IL, USA 3Proton Collaborative Group, Bloomington, IN, USA 4ProCure Proton Therapy Center, Oklahoma City, OK, USA

Depth Dose Curves for Different Treatment Types The Physics of Protons Depth Dose Curves for Different Treatment Types High Energy X-Rays Spread Out Bragg Peak (SOBP) 100 80 Relative Dose 60 Chris The Chris / IBA rap The improved dose distributions of protons, as compared to x-rays, allows increased dose delivered to the target volume, translating into improved local control. Reduced dose to non-involved organs and tissues translates into reduced treatment morbidity and improved quality of life; reduced co-morbidity of multi-modality treatments, leading to improved treatment intensity and compliance. Improved local control of malignancies translates into increased probability of survival for a significant proportion of patients. 40 200 MeV Protons 20 Healthy Tissue Tumor Healthy Tissue 5 10 15 20 25 30 Depth in Tissue (cm)

Methods Patients with clinical Stage I (T1c-T2a, PSA<10, Gleason <6) adenocarcinoma of the prostate were entered onto an IRB approved, multi-institutional trial. Eligible patients were randomly assigned to receive either 79.2 CGE in 44 fractions (1.8 CGE per day – Arm I) versus 38 CGE in 5 fractions (7.6 CGE per day – Arm II). All patients had placement of fiducial markers prior to treatment planning. Planning consisted of treatment planning CT scan, with a pelvic MRI obtained (external coils only) to better define the boundaries of the prostate gland. Eligibility requirement included informed consent, AUA symptom score < 16. After treatment, patients are followed with PSA readings and EPIC quality of life indices at 3 months, 6 months and then every 6 months. PTV was defined as 2mm-3mm around the prostate. An eval-PTV was included the PTV with a 5mm in the lateral expansion. Field design was optimized for 95% coverage of the eval-PTV. All patients were treated with daily marker based IGRT. Most patients had MRI soft tissue registration.

Results The study was opened in Chicago in December, 2010, and in Oklahoma City in August, 2011. As of February 10, 2012, a total of 24 patients have been accrued to the study. Fifteen patients have completed treatment and have undergone review of acute toxicity during treatment. Minor changes in the proximal and/or, distal margin, MRI registration, or prostate contouring were done for almost all cases during QA external review before treatment. However, none of them would have produced target under-dosage. All patients completed treatment as specified in the protocol without any major violations.

Results All 15 patients had Grade 0-1 genitourinary and gastrointestinal toxicity. Six patients (3/8 in Arm I and 3/7 in Arm II) experienced grade 2 toxicity (primarily dermatitis or fatigue). There has been no grade 3 or higher acute toxicity. For all patients acute toxicity was minimal with no grade 2 or higher GU AE other than the use of alpha blockers during treatment in 23% (5/22) of patients. No grade 2 or higher GI AE were seen. Hyperpigmentation/redness was seen in 2 patients. No grade 3 or higher AE were seen. AUA score returned to baseline before the first follow up (see table). AUA and EPIC scores were unchanged for both arms compared to baseline (see table) except for the EPIC sexual domain. Sexual QOL is multifactorial and relative changes can be seen with a sensitive instrument. However, longer follow up and larger cohort will be necessary to define real changes over time in this domain.

Standard course vs hypofractionated protons for prostate cancer Baseline 3 mo 6 mo AUA Symptom Score Arm A 4.3 3.3 7.0 Arm B 5.7 5.8 7.7

Standard course vs hypofractionated protons for prostate cancer Baseline 3 mo 6 mo EPIC GU Arm A 85 86 83 Arm B 88 81

Standard course vs hypofractionated protons for prostate cancer Baseline 3 mo 6 mo EPIC GI Arm A 98 90 94 Arm B 93

Standard course vs hypofractionated protons for prostate cancer Baseline 3 mo 6 mo EPIC Sexual Arm A 67 77 58 Arm B 52 45 61

Standard course vs hypofractionated protons for prostate cancer Baseline 3 mo 6 mo EPIC Hormonal Arm A 99 98 95 Arm B 93 88

Conclusions Patients have completed the study treatment thus far with no untoward acute toxicity. None of the patients has experienced grade 2 or higher acute GI or GU toxicity. We continue to accrue patients to the study. Based on the initial results showing no significant difference in acute toxicity, we have modified the randomization to a 2:1 ratio (2 patients randomized to Arm A [5 fractions] for every one patient randomized to Arm B [standard arm – 44 fractions]). This allows for a smaller number of patients to reach the intended endpoints. There will be a total expected accrual of 197 patients over the next 2 years.

The CDH Proton Center, A Procure Center, Warrenville, IL

Treatment Rooms 15

ProCure Treatment Centers, Inc ProCure Treatment Centers, Inc. content is provided for informational and educational purposes only, and is not intended as medical advice, nor is it intended to create any physician-patient or clinical relationship. Please remember that this information should not substitute for a visit or a consultation with a healthcare provider. The views or opinions expressed in the resources provided do not necessarily reflect those of ProCure Treatment Centers, Inc.